The article discusses how Insitro, a startup using machine learning for drug discovery, is leveraging AI to develop new medicines more efficiently. Daphne Koller, the CEO, explains that traditional drug development relies heavily on human intuition and trial-and-error, which can be slow and costly. Insitro aims to use AI models trained on vast datasets to uncover new biological insights and identify promising drug candidates. The company has partnerships with major pharmaceutical firms to apply its AI platform to various diseases. Koller emphasizes that AI won’t replace human experts but can augment and accelerate their work by rapidly analyzing data and generating hypotheses to test. While challenges remain in translating AI findings to real-world treatments, Insitro believes its approach can revolutionize the drug discovery process and ultimately bring new therapies to patients faster.
Source: https://abcnews.go.com/Business/wireStory/drugs-ai-insitro-ceo-machine-learning-teach-big-116383264